Literature DB >> 699481

Interaction of chloramphenicol with phenytoin and phenobarbital. Case report.

J R Koup, M Gibaldi, P McNamara, D M Hilligoss, W A Colburn, E Bruck.   

Abstract

The effect of chloramphenicol therapy (48 mg/kg/day) on the serum concentrations of phenytoin and phenobarbital was studied in a patient previously stabilized on anticonvulsant medications. Phenytoin, 12 mg/kg/day, and phenobarbital, 5 mg/kg/day resulted in serum concentrations averaging 10.8 microgram/ml before and 30.5 microgram/ml, after chloramphenicol therapy. A reduction in dose of both phenytoin and phenobarbital was required to minimize adverse effects during the course of chloramphenicol therapy. An average daily dose of phenytoin of 9.1 mg/kg resulted in an average serum concentration of 17.8 microgram/ml. A daily dose of phenobarbital of 4.0 mg/kg resulted in an average serum concentration of 37.1 microgram/ml. These changes indicate 50.5% and 40.4% decreases in clearance of phenytoin and phenobarbital. Multiple-dose nonlinear regression analysis of phenytoin and phenobarbital serum concentration data obtained during chloramphenicol therapy indicated a 62.5% and a 29.5% decrease in clearance. Subsequent serum concentration monitoring demonstrated a similar reduction in phenobarbital clearance when chloramphenicol was added to phenobarbital alone.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 699481     DOI: 10.1002/cpt1978245571

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis.

Authors:  Verena Hafner; Nadine Albermann; Walter E Haefeli; Friedrich Ebinger
Journal:  Antimicrob Agents Chemother       Date:  2008-09-15       Impact factor: 5.191

Review 2.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 3.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

4.  Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses.

Authors:  D F Gerken; R A Sams
Journal:  J Pharmacokinet Biopharm       Date:  1985-10

Review 5.  Drug interactions with phenytoin.

Authors:  E Perucca; A Richens
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

Review 6.  Adverse antibiotic drug interactions.

Authors:  A J Bint; I Burtt
Journal:  Drugs       Date:  1980-07       Impact factor: 9.546

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate.

Authors:  P J Ambrose
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

Review 9.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

10.  Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes.

Authors:  Ji-Young Park; Kyoung-Ah Kim; Su-Lyun Kim
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.